Science Pool

BSL3 High Throughput Screening Capabilities Fact Sheet

Posted by Evotec on Mar 8, 2022 5:05:24 PM

With more then 15 years of screening experience in anti-infectives, including antibacterials and antivirals, Evotec's medium throughput and high throughput screening expertise extends to BSL2+ and BSL3 containment level. 

DOWNLOAD NOW

Tags: Fact Sheets, Hit & Target ID/Validation, Anti-Infectives

Anti-Infective Virology Fact Sheet

Posted by Evotec on Mar 8, 2022 4:53:46 PM

Download this fact sheet to learn more about Evotec's anti-infectives virology platform including: 

  • Full integration
  • Project based flexibility tailoring
  • Development of novel tools


DOWNLOAD NOW

Tags: Fact Sheets, In vitro Biology, Anti-Infectives

E.SOLVE: Solving Bioavailability Challenges Fact Sheet

Posted by Evotec on Mar 2, 2022 1:37:10 PM

RZ_E_SOLVE-Logo+Tagline_211004_Screen_Blue-png

E.SOLVE is Evotec's solution to accelerate your journey to the clinic supporting your formulation strategy as early as possible from discovery to market approval.

Download this fact sheet to learn more about how E.SOLVE's full range of approaches improve solubilization and bioavailability to ensure that your API can progress through the drug discovery development pipeline faster.

DOWNLOAD

Tags: IND Enabling, Fact Sheets, Formulation & CMC, Toxicology & Safety

Regulated ADMET Services Fact Sheet

Posted by Evotec on Mar 2, 2022 1:34:27 PM

Download this fact sheet to learn more about our regulatory ADMET services including:

  • Full support of development projects to fulfill and anticipate regulatory requirements
  • Accelerated development process with a full vision through all drug development phases up to filing
  • Dynamic team of expert scientists capable of handling projects of any complexity in regulated environment
  • Full integration with in-house bioanalytical and safety assessment groups
  • Tailored studies and programs based on specific client needs

DOWNLOAD

Tags: Fact Sheets, ADME/DMPK, IND Enabling Studies/Preclinical Development, Toxicology & Safety

INDiGO-Select Fact Sheet

Posted by Evotec on Mar 2, 2022 1:34:15 PM

Learn more about how our INDiGO-Select services help in profiling and selecting your optimal clinical development candidate with:

  • Enhanced quality profile, speed of delivery, and probability of success of clinical candidates
  • Early identification of developability gaps and liabilities in selection process, enabling thorough
    de-risking of your candidate with flexible advanced lead optimization approaches
  • Managed by skilled discovery scientists and complemented by experienced drug development
    experts in CMC and preclinical development all under one roof

DOWNLOAD

Tags: INDiGO, Fact Sheets, IND Enabling Studies/Preclinical Development, Toxicology & Safety, Clinical Development

Clinical Services Fact Sheet

Posted by Evotec on Mar 2, 2022 1:12:17 PM

Learn more about our clinical services platform including:

  • Fully integrated drug development services supporting preclinical and clinical needs,
    up to regulatory approval and commercial phases
  • Clinical supply suitable from First in Human to Phase III, fully GMP-compliant and
    with capacity to handle active ingredients classified up to OEB5 (OEL>0.5 µg/m³)
  • Additional capabilities such as API, formulation development, sample management, PK and statistical analyses, and metabolism

DOWNLOAD

Tags: INDiGO, Fact Sheets, IND Enabling Studies/Preclinical Development, Clinical Development

Abuse Liability Fact Sheet

Posted by Evotec on Feb 10, 2022 11:30:19 AM

Learn more about our abuse liability services including:

  • Compound characterization
  • Pharmacological assessment
  • Preclinical Behavioral studies
  • Integration within a multidisciplinary full-scope clinical-enabling program with chemistry,
    pharmacology, DMPK, safety assessment, regulatory and clinical support, all driven by our drug
    development experts

DOWNLOAD

Tags: INDiGO, Fact Sheets, IND Enabling Studies/Preclinical Development

INDiGO: Fastest Route to the Clinic Fact Sheet

Posted by Evotec on Feb 10, 2022 11:16:44 AM

Learn more about INDiGO and Evotec's integrated preclinical development capabilities to de-risk and accelerate IND-enabling programs:

  • Typically, drug candidates can be advanced from candidate selection to IND-submission in 48–52 weeks
  • Our experienced team not only executes R&D projects, but also proactively contributes to your scientific strategy
  • Clients can either opt for the full INDiGO platform or selected preclinical development and CMC components

DOWNLOAD

Tags: pre-clinical development, INDiGO, Fact Sheets, IND Enabling Studies/Preclinical Development

Pathology, Necropsy and Histology Fact Sheet

Posted by Evotec on Feb 10, 2022 11:06:45 AM

Learn more about our pathology services including:

  • GLP certification with highest quality standards and an impeccable regulatory inspection history
  • Unparalleled flexibility with all capabilities in-house and under one roof
  • ACVP/DECVP, MRCPATH, DECLAM, DECVCP qualified pathologists/clinical pathologists

DOWNLOAD

Tags: Pathology, Fact Sheets, IND Enabling Studies/Preclinical Development

Safety Assessment Fact Sheet

Posted by Evotec on Feb 10, 2022 10:01:32 AM

Learn more about our safety assessment services including:

  • Toxicology core capabilities
  • Safety pharmacology (GLP) studies
  • Genetic toxicology (GLP) studies
  • Additional capabilities such as bioanalytical method development and GLP validation, DMPK, immunoassays, immunogenicity testing, immunotoxicology assays

DOWNLOAD

Tags: INDiGO, Fact Sheets, ADME/DMPK, IND Enabling Studies/Preclinical Development, Toxicology & Safety